Small Cell Lung Cancer Salvage

My Take: A promising salvage ES-SCLC agent, though with an immunotherapy-average cost

Name: Tarlatamab-dlle (Brand name: Imdelltra)

Class:  Bispecific T-cell engager (BiTE) antibody

Usefulness: Treatment of extensive-stage small cell lung cancer (ES-SCLC) in adults who have received prior chemotherapy. ES-SCLC commonly recurs and requires salvage treatment.

Method of Action: A bispecific antibody that binds to DLL3 (Delta-like ligand 3) on tumor cells and CD3 on T cells, redirecting the immune system to attack DLL3-expressing cancer cells.

Potential Market: SCLC accounts for 13–15% of lung cancers in the U.S. with a prediliction for recurrence, and subsequent salvage treatment portends a market of over $500 million globally.

Competing Agents:

• Lurbinectedin (Zepzelca) – another second-line option for SCLC

• Immune checkpoint inhibitors like atezolizumab and durvalumab (used in first-line settings)

• Chemotherapy (topotecan, irinotecan), though with lower efficacy in relapsed disease

Cost to Consumer: Launch pricing is $20,000–$30,000 per cycle, similar to other BiTE therapies and immuno-oncology agents, with overall cost dependent on number of cycles. Insurance coverage is likely for approved indications.

Unusual Fact: Tarlatamab is Amgen’s second BiTE therapy after Blincyto (blinatumomab), but the first to target a solid tumor.